NYSE · Healthcare
Stereotaxis, Inc. (STXS)
As-reported financials and recent SEC filings for Stereotaxis, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$32.4M
Net income
$-21.6M
Net margin
-66.8%
Diluted EPS
$-0.25
ROE
-160.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $32.4M | $26.9M | $26.8M | $28.1M | $35.0M |
| Gross profit | $17.1M | $14.6M | $14.9M | $18.5M | $23.2M |
| Operating income | $-22.1M | $-24.7M | $-21.8M | $-18.8M | $-12.9M |
| Net income | $-21.6M | $-24.0M | $-20.7M | $-18.3M | $-10.7M |
| Diluted EPS | $-0.25 | $-0.30 | $-0.27 | $-0.26 | $-0.16 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →42026-07-01
View on EDGAR →SD2026-05-29
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →Largest Healthcare peers
Go deeper on STXS
Search Stereotaxis, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.